[1]杨义明,杜钢军,林海红.沙利度胺治疗肝癌的实验研究[J].南方医科大学学报,2005,(08):925-928.
　YANG Yi-ming,DU Gang-jun,LIN Hai-hong.Experimental study of thalidomide for treatment of murine hepatocellular carcinoma[J].Journal of Southern Medical University,2005,(08):925-928.
点击复制

沙利度胺治疗肝癌的实验研究()
分享到：

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2005年08期
页码:
925-928
栏目:
出版日期:
2005-08-01

文章信息/Info

Title:
Experimental study of thalidomide for treatment of murine hepatocellular carcinoma
作者:
杨义明1;  杜钢军2;  林海红2
1. 河南大学第一附属医院肿瘤科, 河南, 开封, 475001;
2. 河南大学药学院, 河南, 开封, 475001
Author(s):
YANG Yi-ming1;  DU Gang-jun2;  LIN Hai-hong2
1. Department of Oncology, First Affiliated Hospital, Henan University, Kaifeng 475001, China;
2. College of Pharmacy, Henan University, Kaifeng 475001, China
关键词:
沙利度胺; 肝癌; 实体型; 腹水型; 阿霉素
Keywords:
thalidomide; hepatocellular carcinoma;  solid/ascitic; doxorubicin
分类号:
R73-36;R735.7
摘要:
目的 研究沙利度胺对肝癌的治疗作用。方法 采用小鼠肝癌移植性模型,观察沙利度胺对实体型和腹水型肿瘤的治疗作用。结果 沙利度胺按每日200mg/kg连续给药10d,能明显抑制肝癌实体型肿瘤的生长,不降低小鼠血细胞数及淋巴细胞增殖;对腹水型肿瘤小鼠虽无明显生命延长作用,但沙利度胺与阿霉素联合用药对肝癌实体型及腹水型均有协调抗肿瘤作用,且可阻止阿霉素造成的小鼠血细胞减少、免疫功能降低。沙利度胺日剂量200mg/kg能明显增加肿瘤组织坏死,促进肿瘤组织边缘淋巴细胞侵润。结论 沙利度胺对小鼠肝癌有确切治疗作用,与阿霉素联合用药效果更好。
Abstract:
Objective To study the therapeutic effect of thalidomide(Tha) on murine hepatocellular carcinoma. Methods In murine transplanted hepatoma model, thalidomide was administered intragastrically alone (200 mg/kg daily for 10 days) or in combination with doxorubicin. The antitumor activity of Tha was observed in solid and ascitic tumor models. Results Tha induced significant growth inhibition of solid hepatoma without obvious toxicity on peripheral blood cells and lymphocyte proliferation. Although Tha alone had no effect on the survival of mice with ascitic tumor, it showed a synergistic antitumor activity in combination with doxorubicin (Dox) in both solid and ascitic tumor models. Moreover, Tha reduced Dox-induced cytopenia and immunosuppression. Histological analysis of Tha-treated tumors revealed remarkably enhanced tumor necrosis and lymphocyte infiltration on the edge of tumor tissues. Conclusion Tha has definite therapeutic effect on murine hepatoma, and the combination with Dox shows an enhanced therapeutic potential.

参考文献/References:

[1] Bressoud A, Schwab BZ. Thalidomide: (re)discovery of a not very dear old molecule[J]. Rev Med Suisse Romande, 2003, 123 (4):238-40.
[2] Singhal S, Mehta J. Thalidomide in cancer[J]. Biomed Pharmacother, 2002, 56(1): 4-12.
[3] 翟羽,吕占军.反应停对小鼠肝癌细胞H22移植瘤生长的影响[J].癌症,2003,22(12):1301-6.Zhai Y.Lu ZJ.Effect of thalidomide on tumor growth in mouse hepatoma H22 model[J].Ai Zheng,2003,22(12):1301-6.
[4] 许启泰,杜钢军,陈百泉.美蓝的抗肿瘤作用[J].中国药理学通报,2002,18(3):352-3.Xu QT, Du GJ, Chen BQ. Antitumor action of methylene blue[J].Chin Pharmacol Bull, 2002, 18(3): 352-3.
[5] Myoung H, Hong SD, Kim YY, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma[J]. Cancer Lett,2001, 163(2): 191-200.
[6] 杜钢军,林海红,许启泰托盘根提取物对不同细胞的影响[J].中国药科大学学报,2001,32(6):468-70.Du GJ, Lin HH, Xu QT. Effect of ethanol extract of roots of rubus crataegifolius on tumor cells[J]. J Chin Pharm Univ, 2001, 32(6):468-70.
[7] Raje N, Kenneth C. Thalidomide and immunomodulatory drugs as cancer therapy[J]. Oncology, 2002, 14(6): 635-40.
[8] D’Amato RJ, Loughman MS, Flynn E. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-5.
[9] 平宝红,陈琪,周淑云,等.反应停治疗老年难治性多发性骨髓瘤1例报告[J].第一军医大学学报,2002,22(10):954.Ping BH,Chen Q,Zhou SY,et al.Treatment of old refractory multiple myeloma withthalidomide:report of one case[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2002,22(10):954.
[10] 杨义明,杜钢军,宋华勇,等沙利度胺治疗难治性多发性骨髓瘤的临床研究[J].临床荟萃,2005,20(2):97-8.Yang YM,Du GJ,Song HY,et al.Clinical study on thalidomide in multiple myeloma[J].Clin Focus,2005,20(2):97-8.
[11] 李峰敏,王玉荣,徐建民.反应停诱导骨髓瘤细胞株(KM3)凋亡的初步研究[J].中国临床医学,2002,9(1):9-11.Li FM, Wang YR, Xu JM. Induction of apoptosis by thalidomide in KM3 myeloma cell line[J]. Clin Med J Chin, 2002, 9(1): 9-11.
[12] Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse comeal model of neovascularization[J]. Exp Eye Res, 1997, 64(6): 971-8.
[13] Rajkumar Sv, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma[J]. Mayo Clin Proc, 2000,75(9): 897-901.
[14] Karrow NA, Guo TL, Zhang LX, et al. Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study[J]. Int Immunopharmacol, 2003, 3(10-11): 1447-56.
[15] 杨义明,杜钢军,林海红,等.反应停对HL-60细胞马利兰耐药的逆转作用[J].郑州大学学报(医学版),2005,40(2):300-2.Yang YM, -Du GJ, Lin HH, et al. Reverse effect of thalidomide on myleran-resistant HL-60 cells[J]. J Zhengzhou Univ (Med Sci),2005, 40(2): 300-2.
[16] Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives[J]. Leukemia Res, 2004, 28(4):325-32.

相似文献/References:

[1]陈耿臻,韩慧,许铭炎,等. 重组腺病毒ADV-TK 基因的构建及其对肝癌细胞的杀伤作用[J].南方医科大学学报,2010,(08):1887.
　CHEN Geng-zhen,HU Hui,XU Ming-yan,et al. Construction of recombinant adenovirus containing TK gene and its effect against human liver cancer cells[J].Journal of Southern Medical University,2010,(08):1887.
[2]凌志海,孙权权,张耀伟,等.吉西他滨增强肝癌HepG2细胞体外辐射敏感性的机制研究[J].南方医科大学学报,2011,(12):1993.
[3]陈建发,李宇华,陈引香,等.Apollon siRNA提高肝癌细胞化疗敏感性的实验研究[J].南方医科大学学报,2011,(10):1701.
[4]季锡清,李朝龙,杨进城,等.血流阻断的缺血预处理技术在肝癌切除术中的应用[J].南方医科大学学报,2004,(01):66.
　JI Xi-qing,LI Chao-long,YANG Jin-cheng,et al.Application of ischemic preconditioning before hepatic vascular exclusion for resection of hepatocellular carcinoma[J].Journal of Southern Medical University,2004,(08):66.
[5]王素珍,孟维静,安洪庆,等.基于倾向指数匹配法的肝癌病人疗效评价[J].南方医科大学学报,2012,(09):1234.
[6]阳洁,覃贵慧,陈军泽.慢病毒介导shRNA靶向下调Cx26表达对人高侵袭性肝癌细胞上皮间质转化及侵袭的影响[J].南方医科大学学报,2014,(12):1743.
[7]肖芦山,邹雪晶,胡威,等.microRNA-107在肝癌中的表达及临床意义[J].南方医科大学学报,2016,(07):974.
[8]玉艳红,原彤彤,黄力毅,等.外周血单核细胞hFgl2蛋白表达与不同临床类型肝病的关系[J].南方医科大学学报,2013,(03):436.
[9]戴小珍,熊新,王兰,等.CXCR7-shRNA慢病毒载体对人肝癌细胞生长及侵袭能力的抑制作用[J].南方医科大学学报,2013,(07):994.
[10]曲凯,林婷,魏吉超,等.Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in HepG2 cells[J].南方医科大学学报,2013,(09):1253.

备注/Memo

备注/Memo:
基金项目:Natural Science Foundation of Henan University(04YBRW063)
通讯作者:YangYi-ming(1966-),Tel:0378-5661692
更新日期/Last Update: 1900-01-01